Journal: Journal of Clinical Microbiology

Article Title: Streamlining HIV Testing for HIV Preexposure Prophylaxis

doi: 10.1128/JCM.01540-14

Figure Lengend Snippet: Theoretical PoC algorithms for 2 parallel or sequential rapid tests with HIV-1 viral load (VL) confirmation, using the 50,260 time point evaluations from the iPrEx study.

Article Snippet: Within 15 days of collecting samples, serology was confirmed by Western blotting (WB) with either the New LAV Blot I (Genetic Systems, Bio-Rad, Hercules, CA) or Cambridge Biotech HIV-1 WB kit (Maxim Biomedical, Rockville, MD), depending on the site.

Techniques:

Journal: Advanced Techniques in Diagnostic Microbiology

Article Title: Molecular Techniques for Blood and Blood Product Screening

doi: 10.1007/978-1-4614-3970-7_28

Figure Lengend Snippet: Licensed/approved clinical assays for infectious agents (Source: Center for Biologics Evaluation and Research, US Food and Drug Administration [ 48 ])

Article Snippet: OraSure HIV-1 Western Blot Kit , WB , Oral fluid , Diagnostic supplemental , OraSure Technologies, Bethlehem, PA , 6/3/1996.

Techniques: HBsAg Assay, Enzyme-linked Immunosorbent Assay, Diagnostic Assay, Clinical Proteomics, Virus, Stripping Membranes, Western Blot, Viral-load Assay, DNA Sequencing, Amplification, Biomarker Discovery, Infection, Reverse Transcription, Polymerase Chain Reaction, Quantitation Assay, T. Cruzi Assay

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Article Title: Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens

doi: 10.1016/j.jcv.2020.104344

Figure Lengend Snippet: Results from HIV assays b in early infection samples characterized by Fiebig stage

Article Snippet: All six samples in Fiebig stage V (HIV-1 WB-positive minus-p31) were reactive in both plasma and blood. table ft1 table-wrap mode="anchored" t5 Table 2: caption a7 n with HIV test result: c Fiebig Stage: RNA a Architect Determine GS+O Geenius HIV-1 WB G4 LAB G4 POC n Pos Ag/Ab-R Ag-R Ag/Ab-R Ab-R IgG/IgM R Neg Ind Pos Interpretation IgG R IgG R Eclipse 5 0 0 0 0 0 0 5 0 0 Neg 0 0 I 4 4 0 0 0 0 0 4 0 0 Neg 0 0 II 4 4 4 3 0 0 0 4 0 0 Neg 0 0 III 6 6 6 4 2 3 6 4 2 0 Neg 1 0 IV 13 13 13 7 6 11 12 4 5 4 HIV-1 Ind 7 2 V 6 6 6 0 0 6 6 0 0 6 HIV-1 Pos d 6 6 Open in a separate window a Plasma testing for HIV-1 RNA included results from either Roche CAP/CTM or Roche Amplicor Monitor. b Plasma testing: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, Geenius HIV-1/2 Supplemental Assay (IgG), HIV-1 WB: Cambridge Biotech HIV-1 Western blot Kit or Bio-Rad Genetic Systems HIV-1 (IgG), GS+O: GS HIV-1/HIV-2 PLUS O EIA (IgG/IgM), G4 LAB: MedMira Reveal G4 LAB S/P (IgG Rapid Test).

Techniques: Infection

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Article Title: Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens

doi: 10.1016/j.jcv.2020.104344

Figure Lengend Snippet: Results of FDA-approved diagnostic assays a in nine discordant samples from seroconverters (SC) with G4 LAB-plasma Reactive and POC-blood Nonreactive results

Article Snippet: All six samples in Fiebig stage V (HIV-1 WB-positive minus-p31) were reactive in both plasma and blood. table ft1 table-wrap mode="anchored" t5 Table 2: caption a7 n with HIV test result: c Fiebig Stage: RNA a Architect Determine GS+O Geenius HIV-1 WB G4 LAB G4 POC n Pos Ag/Ab-R Ag-R Ag/Ab-R Ab-R IgG/IgM R Neg Ind Pos Interpretation IgG R IgG R Eclipse 5 0 0 0 0 0 0 5 0 0 Neg 0 0 I 4 4 0 0 0 0 0 4 0 0 Neg 0 0 II 4 4 4 3 0 0 0 4 0 0 Neg 0 0 III 6 6 6 4 2 3 6 4 2 0 Neg 1 0 IV 13 13 13 7 6 11 12 4 5 4 HIV-1 Ind 7 2 V 6 6 6 0 0 6 6 0 0 6 HIV-1 Pos d 6 6 Open in a separate window a Plasma testing for HIV-1 RNA included results from either Roche CAP/CTM or Roche Amplicor Monitor. b Plasma testing: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, Geenius HIV-1/2 Supplemental Assay (IgG), HIV-1 WB: Cambridge Biotech HIV-1 Western blot Kit or Bio-Rad Genetic Systems HIV-1 (IgG), GS+O: GS HIV-1/HIV-2 PLUS O EIA (IgG/IgM), G4 LAB: MedMira Reveal G4 LAB S/P (IgG Rapid Test).

Techniques: Diagnostic Assay

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Article Title: Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens

doi: 10.1016/j.jcv.2020.104344

Figure Lengend Snippet: Overall Performance and Reactivity of sample sets in G4 LAB and POC Tests

Article Snippet: All six samples in Fiebig stage V (HIV-1 WB-positive minus-p31) were reactive in both plasma and blood. table ft1 table-wrap mode="anchored" t5 Table 2: caption a7 n with HIV test result: c Fiebig Stage: RNA a Architect Determine GS+O Geenius HIV-1 WB G4 LAB G4 POC n Pos Ag/Ab-R Ag-R Ag/Ab-R Ab-R IgG/IgM R Neg Ind Pos Interpretation IgG R IgG R Eclipse 5 0 0 0 0 0 0 5 0 0 Neg 0 0 I 4 4 0 0 0 0 0 4 0 0 Neg 0 0 II 4 4 4 3 0 0 0 4 0 0 Neg 0 0 III 6 6 6 4 2 3 6 4 2 0 Neg 1 0 IV 13 13 13 7 6 11 12 4 5 4 HIV-1 Ind 7 2 V 6 6 6 0 0 6 6 0 0 6 HIV-1 Pos d 6 6 Open in a separate window a Plasma testing for HIV-1 RNA included results from either Roche CAP/CTM or Roche Amplicor Monitor. b Plasma testing: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, Geenius HIV-1/2 Supplemental Assay (IgG), HIV-1 WB: Cambridge Biotech HIV-1 Western blot Kit or Bio-Rad Genetic Systems HIV-1 (IgG), GS+O: GS HIV-1/HIV-2 PLUS O EIA (IgG/IgM), G4 LAB: MedMira Reveal G4 LAB S/P (IgG Rapid Test).

Techniques:

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Article Title: Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens

doi: 10.1016/j.jcv.2020.104344

Figure Lengend Snippet: Results from HIV assays b in early infection samples characterized by Fiebig stage

Article Snippet: All six samples in Fiebig stage V (HIV-1 WB-positive minus-p31) were reactive in both plasma and blood. table ft1 table-wrap mode="anchored" t5 Table 2: caption a7 n with HIV test result: c Fiebig Stage: RNA a Architect Determine GS+O Geenius HIV-1 WB G4 LAB G4 POC n Pos Ag/Ab-R Ag-R Ag/Ab-R Ab-R IgG/IgM R Neg Ind Pos Interpretation IgG R IgG R Eclipse 5 0 0 0 0 0 0 5 0 0 Neg 0 0 I 4 4 0 0 0 0 0 4 0 0 Neg 0 0 II 4 4 4 3 0 0 0 4 0 0 Neg 0 0 III 6 6 6 4 2 3 6 4 2 0 Neg 1 0 IV 13 13 13 7 6 11 12 4 5 4 HIV-1 Ind 7 2 V 6 6 6 0 0 6 6 0 0 6 HIV-1 Pos d 6 6 Open in a separate window a Plasma testing for HIV-1 RNA included results from either Roche CAP/CTM or Roche Amplicor Monitor. b Plasma testing: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, Geenius HIV-1/2 Supplemental Assay (IgG), HIV-1 WB: Cambridge Biotech HIV-1 Western blot Kit or Bio-Rad Genetic Systems HIV-1 (IgG), GS+O: GS HIV-1/HIV-2 PLUS O EIA (IgG/IgM), G4 LAB: MedMira Reveal G4 LAB S/P (IgG Rapid Test).

Techniques: Infection

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Article Title: Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens

doi: 10.1016/j.jcv.2020.104344

Figure Lengend Snippet: Results of FDA-approved diagnostic assays a in nine discordant samples from seroconverters (SC) with G4 LAB-plasma Reactive and POC-blood Nonreactive results

Article Snippet: All six samples in Fiebig stage V (HIV-1 WB-positive minus-p31) were reactive in both plasma and blood. table ft1 table-wrap mode="anchored" t5 Table 2: caption a7 n with HIV test result: c Fiebig Stage: RNA a Architect Determine GS+O Geenius HIV-1 WB G4 LAB G4 POC n Pos Ag/Ab-R Ag-R Ag/Ab-R Ab-R IgG/IgM R Neg Ind Pos Interpretation IgG R IgG R Eclipse 5 0 0 0 0 0 0 5 0 0 Neg 0 0 I 4 4 0 0 0 0 0 4 0 0 Neg 0 0 II 4 4 4 3 0 0 0 4 0 0 Neg 0 0 III 6 6 6 4 2 3 6 4 2 0 Neg 1 0 IV 13 13 13 7 6 11 12 4 5 4 HIV-1 Ind 7 2 V 6 6 6 0 0 6 6 0 0 6 HIV-1 Pos d 6 6 Open in a separate window a Plasma testing for HIV-1 RNA included results from either Roche CAP/CTM or Roche Amplicor Monitor. b Plasma testing: Architect HIV Ag/Ab Combo Assay, Determine HIV-1/2 Ag/Ab Combo, Geenius HIV-1/2 Supplemental Assay (IgG), HIV-1 WB: Cambridge Biotech HIV-1 Western blot Kit or Bio-Rad Genetic Systems HIV-1 (IgG), GS+O: GS HIV-1/HIV-2 PLUS O EIA (IgG/IgM), G4 LAB: MedMira Reveal G4 LAB S/P (IgG Rapid Test).

Techniques: Diagnostic Assay

Journal: BMC Infectious Diseases

Article Title: Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil

doi: 10.1186/1471-2334-9-116

Figure Lengend Snippet: Screening for HCV and HIV infection among pregnant women in Public Health Settings, Central Brazil . Five out of 65 anti HCV-positive/indeterminate women and five out of 38 anti-HIV positive/indeterminate women could not be traced for confirmatory test. Doted lines indicate that indeterminate test results (HCV and HIV) were considered negative.

Article Snippet: In parallel, at least one of the following confirmatory tests were applied: Indirect Immunofluorecence by IFI – HIV1 kit (Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de Janeiro); Immuno Blot (IB) using a NEW LAV BLOT 1 kit (Bio-Rad, France) that detects antibodies against HIV-1 gp160, gp110/120, p68, p55, p52, gp41, p40, p34, p24/25 and p18; Western Blot (WB) for detection of HIV1 and HIV2, using HIV BLOT 2.2 kit (Genelabs ® Diagnostics Pte Ltd, Singapore) and qualitative "Nested" PCR to detect pro viral HIV1 DNA in blood mononuclear cells (50 copies/mL detection limit), performed at the Center of Genomics Laboratory (São Paulo, Brazil).

Techniques: Infection